Found 71 clinical trials
-
Unknown Phase
-
Accepting Seniors
-
Accepting adults
-
Oncology
-
Currently Recruiting
Atezolizumab In Combination With Cabozantinib
People with Renal Cell Carcinoma are asked to participate in a research study being conducted by Montefiore Medical Center.
- 0 views
- 31 Aug, 2020
- 1 location
-
Unknown Phase
-
Accepting pediatric ages
-
Currently Recruiting
Alliance A031203: Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma
Alliance A031203: Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or
- 186 views
- 08 Nov, 2020
- 1 location
-
Multi-country trial
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For females only
-
Currently Recruiting
IRCI Gynae Sarcomas High Grade Uterine Sarcoma
This study aims to investigate a drug called Cabozantinib which belongs to a family of drugs that have effects on tumour growth, blood supply, invasion and spread. Therefore, we want to
- 52 views
- 23 Jan, 2021
- 10 locations
-
Multi-country trial
-
Phase 3 trial
-
Accepting pediatric ages
-
Accepting Seniors
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine
- 26 views
- 24 Jan, 2021
-
Multi-country trial
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear
- 2 views
- 05 Dec, 2020
- 67 locations
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Cabozantinib in High Grade Neuroendocrine Neoplasms
High grade neuroendocrine neoplasm patients are treated with platinum doublets such as carboplatin and etoposide mimicking the current guidelines for small cell lung cancer (SCLC). Unfortunately, recurrences are common and most patients with metastatic disease succumb to it within a year. There is no extensive literature or consensus on second- …
- 0 views
- 03 Dec, 2020
- 1 location
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma
The study aims to evaluate the safety and preliminary efficacy of the combination of cabozantinib and pembrolizumab in advanced melanoma
- 0 views
- 25 Jan, 2021
- 1 location
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)
Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor. Its primary targets are Hepatocyte growth factor receptor protein (MET), vascular endothelial growth factor receptor 1-3
- 46 views
- 02 Nov, 2020
- 12 locations
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
The hypothesis of this study is that the response rate of soft tissue sarcoma will be improved with the addition of PD-1 and CTLA-4 inhibition to cabozantinib, and that cabozantinib priming will
- 0 views
- 17 Jan, 2021
- 2 locations
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For males only
-
Currently Recruiting
Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)
Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): an open-label, single-center, phase 2, single-arm trial (CaboPen)
- 0 views
- 23 Jan, 2021
- 1 location